OR WAIT null SECS
April 11, 2022
Lonza and Asher Biotherapeutics have entered a manufacturing agreement for a cis-targeted IL-2 fusion protein, AB359.
IAVI and Moderna have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health issues.
April 08, 2022
FDA has granted Priority Review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.
ECDC and EMA have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines in the general population.
UK’s MHRA has issued a positive opinion for the Early Access to Medicines Scheme for radioligand therapy in patients with advanced prostate cancer.
April 07, 2022
INCOG Biopharma has completed the construction of its cleanroom production area, marking a milestone in the completion of an overall $100 million investment in a new facility.
April 06, 2022
FDA has accepted Dupixent for Priority Review in patients aged 12 years and older with eosinophilic esophagitis.
Merck has expanded its manufacturing facility in Elkton, Va. to further increase its HPV vaccine supply.
FDA has granted an expanded Emergency Use Authorization to Pfizer and BioNTech’s COVID-19 vaccine boosters in individuals aged 50 years and older.
March 31, 2022
Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.